Sachs Associates’ Post

[Matica Bio│NEWS] Treovir and Matica Bio Forms Strategic Partnership to Advance Innovative Therapies for Pediatric Brain Tumors Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector development and manufacturing, today announced a strategic partnerships with Treovir. The collaboration aims to advance innovative therapies for pediatric patients with brain and other neurological cancers. Matica Bio will provide GMP manufacturing for clinical supplies. #마티카바이오 #Maticabio #CDMO #HSV #단순포진바이러스벡터 #소아뇌종양 #임상시험 #clinicaltrial #유전자치료제 #genetherapy

Can Viagra Help against Alzheimer’s? A new study, published in the journal Neurology by Adesuyan et al. (2024), is generating buzz: Phosphodiesterase type 5 inhibitors (such as Viagra) might reduce the risk of developing Alzheimer’s disease. The researchers analyzed data from men with erectile dysfunction and discovered that those who took Viagra had a lower risk of Alzheimer’s. However, before celebrating Viagra as a miracle cure, it’s important to note some limitations of the study. Being an observational study, it demonstrates correlations but not causation. Additionally, potential influencing factors, such as lifestyle and genetic predispositions, were not fully accounted for. While the results are promising, further research is needed to confirm the actual effect of Viagra on Alzheimer’s. Until then, caution is advised… __________________ Studies (just a small selection): Adesuyan, M., Jani, Y. H., Alsugeir, D., Howard, R., Ju, C., Wei, L., & Brauer, R. (2024). Phosphodiesterase type 5 inhibitors in men with erectile dysfunction and the risk of alzheimer disease: a cohort study. Neurology, 102(4), e209131. Gohel, D., Zhang, P., Gupta, A. K., Li, Y., Chiang, C. W., Li, L., … & Cheng, F. (2024). Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons. Journal of Alzheimer’s Disease, (Preprint), 1-15. Hu, E., Li, T. S., Wineinger, N. E., & Su, A. I. (2023). Association study between drug prescriptions and Alzheimer’s disease claims in a commercial insurance database. Alzheimer’s Research & Therapy, 15(1), 118. Prickaerts, J., Heckman, P. R., & Blokland, A. (2017). Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. Expert opinion on investigational drugs, 26(9), 1033-1048. https://lnkd.in/ex7n5Jxw

AbbVie has announced the acquisition of Aliada Therapeutics, integrating Aliada's innovative MODEL platform, designed to target Alzheimer's disease and enhance blood-brain barrier penetration. This acquisition strengthens AbbVie’s growing neuroscience pipeline, reflecting the industry's renewed focus on CNS and neurology sectors. CNS Biotech Market in Demand The CNS therapeutics market is experiencing significant growth, driven by advances in treatments for Alzheimer's, schizophrenia, and Parkinson's disease. The market is projected to grow from $143.1 billion in 2024 to over $218 billion by 2030, with an annual growth rate of 7.2%. Increasing demand for novel neurotherapies and drug delivery systems, including technologies that bypass the blood-brain barrier, is accelerating acquisitions and partnerships within the sector. Other Major CNS Deals in 2023-2024: - AbbVie also acquired Cerevel Therapeutics for $8.7 billion, boosting its portfolio in schizophrenia and Parkinson’s treatments. - Merck purchased Caraway Therapeutics to expand its research in neurodegenerative diseases. - Bristol-Myers Squibb acquired Karuna Therapeutics for $14 billion, targeting innovative treatments for schizophrenia and mood disorders. It’s an exciting time for the industry, with neuroscience breakthroughs taking center stage! #Biotech #CNS #Neurology #AbbVie #AliadaTherapeutics #Pharmaceuticals https://lnkd.in/ek-8hpBt

🩸 New report out now: Hematologic Cancer Opportunities for Patient Equality (HOPE): Geographic Disparities in Access, Reimbursement, and Hematology Therapy Utilization. Hematological cancer incidence is projected to increase by 55% by 2050, from 1.3 million in 2022 to 2.03 million in 2050. Yet trends in hematological malignancy access aren’t as well understood as oncology patient access. This report showcases: ✅ Trends regarding the availability of therapies for hematological malignancies across selected countries. ✅ Trends in overall regulatory approvals, health technology assessments, reimbursement, and final therapy usage have been analyzed for drugs. ✅ A comparison of these trends with similar ones for solid tumors. ✅ Important dynamics associated with hematology, such as the prevalence of combination therapies and approval based on Phase I/II or III data. ✅ Potential drivers of these trends and the challenges faced by hematology drugs. ✅ The implications of these findings and provides a call to action for policies. Download the report here: https://bit.ly/4bZ2kAd #Hematology #HealthEquity #GlobalHealth

The latest IQVIA HOPE Report (Hematologic Cancer Opportunities for Patient Equality) details the projected 55% increase in hematological cancer cases by 2050, accessibility to therapies for hematological malignancies, and trends towards an equitable system. Download your copy here: https://bit.ly/3xJqCPD #hematology #hematologyoncology #HealthEquity #GlobalHealth

Analysis Identifies International Treatment Outcomes, Patterns in Individuals With NDMM: The authors found that overall survival in patients with newly diagnosed multiple myeloma was longest for those receiving first-line autologous stem cell transplantation. #finance #pharmacy #lifesciences

More good news! Bayer subsidiary BlueRock Therapeutics has reported encouraging 24-month outcomes from the Phase I exPDite clinical study of bemdaneprocel, a novel cell therapy for Parkinson’s disease. This therapy is currently the most advanced clinical option available in the United States for patients suffering from this condition. This news represents a significant step forward in our ongoing fight against neurological diseases. As we continue to make progress in research and development, I look forward to a future where diagnostics play a crucial role in guiding personalized therapies. The innovative tools and treatments on the horizon hold great promise for improving the lives of those affected by Parkinson’s and other neurological disorders. For more information on our side of development, there is still time to register for the at The Parkinson’s Solution Summit 2.0: https://lnkd.in/eG6qM-hf #dementia #alzheimers #venturecapital #angelinvestor #cancer #hivaids  #bioOS #biotechnology #diagnostics #innovation #technology #management #startups #liquidbiopsy #neurodegenerativediseases #multiplesclerosis #parkinsonsdisease #alzheimersdisease #longhaulers #longcovid #humangenome #onetestonelife #longevity #artificialintelligence #rna #rnaseq #personalizedprevention #PersonalizedMedicine #ClinicalResearch #COVID19 #Parkinsons #dementia #alzheimers #venturecapital #angelinvestor #cancer #hivaids  #bioOS #biotechnology #diagnostics #innovation #technology #management #startups #liquidbiopsy #neurodegenerativediseases #multiplesclerosis #parkinsonsdisease #alzheimersdisease #longhaulers #longcovid #humangenome #onetestonelife #longevity #artificialintelligence #rna #rnaseq #personalizedprevention #PersonalizedMedicine #ClinicalResearch #COVID19 #Parkinsons https://lnkd.in/eV5z3pA8

Radiopharmaceuticals are a rapidly evolving class of drugs that combine radioactive isotopes with biological molecules to target and treat specific diseases, most notably in oncology and neurology. These agents have a dual role: as diagnostic tools, they help locate and visualize tumors or diseased tissue while as therapeutic agents, they deliver targeted radiation to destroy those same cells. However, over the past few decades, radiopharmaceuticals have undergone a significant transformation. Read more on the mechanism, challenges, significant deals and more on Labiotech.eu: https://lnkd.in/e8THJDvj #Radiopharmaceuticals #Medtech #Diagnostics

The #CNS therapeutics market is poised for significant growth, driven by the rising prevalence of #neurodegenerativediseases, #traumatic CNS injuries, and brain cancer. Increased research and development efforts, coupled with substantial investments, are fueling advancements in the field. Want To Know More: https://lnkd.in/dy7YgdHf #AMR #CNSTherapeutics #NeurodegenerativeDiseases #BrainCancer #TraumaticInjuries #MedicalResearch #Pharmaceuticals #Biotechnology #HealthcareInnovation #DrugDevelopment #Neurology #HealthcareTrends #AgingPopulation #MedicalAdvancements #CNSMarket #TherapeuticInterventions